Advanced Biological Laboratories has been granted additional patents in Hong Kong (HK1121187) to further protect its intellectual property and reinforce the already existing core patent entitled ”
Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof” (US Patent 8,367,317, Publication nº US8367317 B2).
Laboratories, virologists and microbiologists:
Clinics, clinicians and pathologists:
Advanced Biological Laboratories (ABL) S.A. and Technogenetics (TGX) today announced that they entered into an exclusive distributor agreement of the DeepChek® SingleRound Assay and software product lines in Italy. The DeepChek® SingleRound Assay product line combines target-specific PCR reagents with in vitro diagnostic software, both compatible with either Sanger or Next Generation Sequencing platforms for Virology applications (like HIV, Hepatitis C, Hepatitis B first, then for HPV, CMV, Flu, Herpes and Tuberculosis).
ABL continues developing its technology offer with Nadis(r) technology as a specialized patient management system. Nadis is widely used in France, this completes the offer for the French market in plus of microbiology reagents and software.
ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C.
ABL is pleased to invite you to attend the viral typing webinar held with Thermo Fisher Scientific about the combination of their next generation sequencing systems and the ABL DeepChek downstream analysis software, for HIV, HBV and HCV. Tuesday, 10th May 2016 — 5 pm CET / 4 pm GMT / 11 am EST Register now for this free viral typing webinar.
ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.
ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, ViroScore® and DeepChek®. To know more, please click here.
Barcelona, 16th February 2015. Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations.
The study, published in the Journal of Clinical Microbiology, is a collaboration between all the members of the Networked Biomedical Research Center for Hepatic and Digestive Diseases (CIBERehd), Roche and ABL. It is funded with the CDTI MINECO IDI 20110115.
ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antiviral Agents which has been developed together with the Spanish Association for Liver Diseases.
University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS). See the press release.
https://sg.finance.yahoo.com/news/advanced-biological-laboratories-signs-agreement-130000299.html
http://www.eurekalert.org/pub_releases/2015-01/uhcm-abl011315.php
University Hospitals signs agreement with Luxembourg company to offer new HIV drug resistance test.
Two new DeepChek® applications dedicated to viral hepatitis B (HBV) and hepatitis C (HCV) are now available in BaseSpace, the Illumina’s dedicated applications store and cloud-based informatics community dedicated to advancing genomic analysis. See the press release about BaseSpace and Illumina.
ABL will be participating to the next Illumina BaseSpace Worldwide Developers Conference (WWDC) in San Francisco on the 8th and 9th of December 2014.
ABL S.A, The University of Hong Kong and The Hong Kong Polytechnic University are launching their collaborative tuberculosis (TB) project to develop a deep-sequencing assay and its tailored bio-informatics pipeline. View more